Quest Diagnostics (DGX) PT Raised to $160 at Jefferies

July 23, 2021 8:44 AM EDT
Get Alerts DGX Hot Sheet
Price: $149.88 -2.1%

Rating Summary:
    16 Buy, 13 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 4 | Down: 5 | New: 5
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Jefferies analyst Brian Tanquilut raised the price target on Quest Diagnostics (NYSE: DGX) to $160.00 (from $155.00) while maintaining a Buy rating.

The analyst commented, "e are positive on DGX given our view that continued improvement in core fundamentals -- driven by accelerating payor-driven share gains, organic growth seen in recent hospital lab deals, and mgmt efforts to drive operating efficiencies -- will contribute to improved earnings growth and EPS upside that translates to positive stock momentum. Mgmt's 2H21 guidance seems conservative and could benefit from the emerging spike in COVID
cases due to the Delta variant."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co, Earnings